News

The U.S. Food and Drug Administration approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults. “Emgality provides…
Read More...

Aldevron announced expansion plans for a 14-acre campus at its headquarters in Fargo, N.D. Phase one construction will begin in August. Upon completion of the campus, the annual…
Read More...

Thermo Fisher Scientific and Newomics will combine their expertise and innovative technologies to develop and optimize sensitive, robust and reproducible microflow LC-MS workflows for…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved Merck’s supplemental New Drug Application (sNDA) for…
Read More...

AstraZeneca has presented three-year overall survival (OS) results from the Phase III PACIFIC trial of Imfinzi (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC)…
Read More...

Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), announced that it has entered into a Master Development and Commercialization Agreement with…
Read More...

Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. It will bring together Gubra’s…
Read More...

Particle Sciences, a Lubrizol LifeSciences company and pharmaceutical contract development and manufacturing organization (CDMO), has broadened its Drug Enforcement Administration (DEA)…
Read More...

Merz, a global leader in neurotoxin therapy, announced the European approval of Xeomin (incobotulinumtoxinA) for the symptomatic treatment of chronic sialorrhea (drooling) due to…
Read More...

Bayer AG and Foundation Medicine, Inc. announced a global collaboration for the development and commercialization of NGS-based companion diagnostics.  This agreement allows for…
Read More...

Armas Pharmaceuticals Inc. and Micro Labs USA, Inc. have announced, the forming of a strategic collaboration to bring select multisource injectable products to the U.S. market. The…
Read More...

Allergan plc and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for…
Read More...

Vibalogics GmbH, a contract development and manufacturing organization (CDMO) focused on complex live biological products, is being acquired by Ampersand Capital Partners, a private…
Read More...

Acerus Pharmaceuticals Corporation announced that it has signed a patent license agreement with the University of Texas at Austin for technology related to the nasal administration of…
Read More...

Modulus Discovery, an early stage global biopharmaceutical company, announced the signing of research data transfer agreement on a specific drug target with Astellas Pharma. Under…
Read More...

Epizyme, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat for the treatment of…
Read More...

Imara, Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies, announced that the U.S. Food and Drug Administration (FDA) has…
Read More...

AgilVax, Inc., a biotechnology company developing targeted antibody-based therapies for the treatment of various cancers, including metastatic breast cancer (MBC), announced that the…
Read More...

Prestige BioPharma announced that European Medicines Agency (EMA) has validated and accepted for review the Marketing Authorization Application (MAA) for its trastuzumab biosimilar…
Read More...

Vetter has reached another important milestone regarding sustainability. Beginning immediately, all German sites of the company will be supplied with only CO2 neutral energy from…
Read More...